Personalized Responses to Dietary Composition Trial 3
Zoe Global Limited · with Massachusetts General Hospital, Stanford University · NCT04735835
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 18+ · All sexes
- Healthy volunteers
- Accepted
- Study type
- Interventional · Not applicable
- Target enrollment
- 250000
- US sites recruiting
- 1
- Study start
- July 20, 2020
- Record last updated
- April 16, 2025
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
The PREDICT 3 study will build on previous research in over 2,000 individuals to further refine machine learning models that predict individual responses to foods, with the aim of advancing precision nutrition science and individualized dietary advice. The study incorporates both standardized and controlled dietary intervention, for the purpose of testing postprandial responses to specific mixed meals, in addition to a free-living period with a dietary record for measuring responses to a large variety of meals consumed in a realistic context, where the role of external factors (e.g. exercise, sleep, time of day) on postprandial responses may be determined. For the first time this PREDICT study is built on top of a commercial product which will allow access to a much larger group of participants who are already collecting large amounts of data through digital and biochemical devices that can contribute to science.
Being studied: Dietary Intervention
Conditions: Diabetes; Heart Diseases; Diet Habit; Diet Modification; Healthy; Obesity; Metabolism; Microbial Colonization
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- Enrolled in the commercial ZOE testing program
- Any sex
- Minimum 18 years of age (minimum 19 years of age in Alabama and Nebraska due to state laws)
- Body mass index (BMI) of greater than or equal to 16.5 kg/m2.
- Living in the continental US states, other than in New York (excluded from the ZOE testing product also as they are unable to access the dried blood spot service provided by Quest), or living in the UK
- Able and willing to comply with the study protocol and provide informed consent.
- Under care for chronic medical conditions (including eating disorders, type 1 diabetes, type 2 diabetes), and confirm they have checked with their primary care physician that this study is safe for them (US cohort only)
Exclusion Criteria
- Cannot safely eat the pre-made test meals which contain standard US ingredients, e.g. due to allergy or recent gastrointestinal surgery, or are unwilling to consume these foods.
- Are pregnant.
- Have had a heart attack (myocardial infarction), stroke/transient ischemic attack (TIA), or major surgery in the last two months.
- Are unable to read and write in English, as the ZOE app is only available in English.
Recruiting US locations
Zoe US Inc.
Needham, MA 02494
Site contact: Brad Reardon · +1866-771-7478 · hello@joinzoe.com
Study contacts (from the official record)
- Meaghan Reardon · 866-771-7478 · meaghan@joinzoe.com
- Dan Sleeper · 866-771-7478 · dan@joinzoe.com
Similar studies in Massachusetts
All weight loss studies in Massachusetts →- RecruitingHealthy volunteersOvernight stay mentioned
The Osteoarthritis Prevention Study
Wake Forest University
- Location
- Boston, MA + 1 other US site
- Eligibility basics
- Ages 50+ · Women only
- RecruitingHealthy volunteersPhase 3
A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
- Location
- Methuen, MA + 55 other US sites
- Eligibility basics
- Ages 18–79
- Recruiting
The RESET System Pivotal Clinical Trial (Protocol Revision K)
Morphic Medical Inc.
- Location
- Boston, MA + 25 other US sites
- Eligibility basics
- Ages 22–65
- RecruitingPhase 3
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes
Hoffmann-La Roche
- Location
- Boston, MA + 43 other US sites
- Eligibility basics
- Ages 18+